NCT02827877View on ClinicalTrials.gov

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

July 2, 2020

Study Completion Date

October 16, 2025

Conditions
HER2 Positive Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
RADIATION

Copper Cu 64-DOTA-Trastuzumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pertuzumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER